Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5608734 | 1.00 | HCAR2 (0.48) | HCAR2KEAP1NFE2L2NPSR1NR1H4 | |
| SCHEMBL9129967 | 1.00 | HCAR2 (0.48) | HCAR2KEAP1NFE2L2NPSR1NR1H4 | |
| SCHEMBL9129957 | 1.00 | HCAR2 (0.48) | HCAR2KEAP1NFE2L2NPSR1NR1H4 | |
| SCHEMBL38250 | 0.98 | HCAR2 (0.50) | HCAR2KEAP1NFE2L2NPSR1NR1H4 | |
| SCHEMBL38251 | 0.98 | HCAR2 (0.50) | HCAR2KEAP1NFE2L2NPSR1NR1H4 | |
| SCHEMBL26696282 | 0.94 | HCAR2 (0.50) | HCAR2KEAP1NFE2L2NR1H4 | |
| SCHEMBL29263941 | 0.89 | HCAR2 (0.55) | HCAR2KEAP1NFE2L2 | |
| SCHEMBL1718737 | 0.89 | — | — | |
| SCHEMBL1718738 | 0.89 | — | — | |
| SCHEMBL27325445 | 0.82 | HCAR2 (0.43) | HCAR2KEAP1NFE2L2NPSR1NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118878514-A | Heterocyclic compounds for modulating NR2F6 | TES制药有限责任公司 | 2024-11-01 | — | — | CN | disclosed |
| EP-4110758-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | Tes Pharma S.r.l. (IT) | 2023-01-04 | — | — | EP | disclosed |
| CN-115427394-A | Heterocyclic compounds for modulating NR2F6 | TES制药有限责任公司 | 2022-12-02 | — | — | CN | disclosed |
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S R L (IT) | 2021-10-21 | — | — | US | disclosed |
| US-11009749-B2 | Liquid crystal display device and method for manufacturing liquid crystal display device | SHARP KABUSHIKI KAISHA (JP) | 2021-05-18 | — | — | US | disclosed |
| US-20190219856-A1 | LIQUID CRYSTAL PANEL, SWITCHABLE MIRROR PANEL AND SWITCHABLE MIRROR DISPLAY | SHARP KABUSHIKI KAISHA (JP) | 2019-07-18 | — | — | US | disclosed |
| WO-2019103897-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | AURANSA INC. (US) | 2019-05-31 | — | — | WO | disclosed |
| US-20180237441-A1 | Chemical Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-08-23 | — | — | US | disclosed |
| US-20170218272-A1 | ALIGNMENT FILM AND LIQUID CRYSTAL DISPLAY DEVICE | SHARP KABUSHIKI KAISHA (JP) | 2017-08-03 | — | — | US | disclosed |
| WO-2017046737-A1 | 1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017046737-A1 | 1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-23 | — | — | WO | disclosed |
| US-9423706-B2 | Electrophotographic photosensitive member, method for producing electrophotographic photosensitive member, process cartridge, and electrophotographic apparatus | CANON KABUSHIKI KAISHA (JP) | 2016-08-23 | — | — | US | disclosed |
| US-20160016860-A1 | METHODS FOR PHOSPHINE OXIDE REDUCTION IN CATALYTIC WITTIG REACTIONS | DUBLIN CITY UNIVERSITY (IE) | 2016-01-21 | — | — | US | disclosed |
| US-20160016860-A1 | METHODS FOR PHOSPHINE OXIDE REDUCTION IN CATALYTIC WITTIG REACTIONS | DUBLIN CITY UNIVERSITY (IE) | 2016-01-21 | — | — | US | disclosed |
| WO-2014140353-A1 | METHODS FOR PHOSPHINE OXIDE REDUCTION IN CATALYTIC WITTIG REACTIONS | DUBLIN CITY UNIVERSITY (IE) | 2014-09-18 | — | — | WO | disclosed |
| US-5545666-A | CARDIOVASCULAR DISORDERS, KIDNEY DISORDERS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1996-08-13 | — | — | US | disclosed |
| EP-0666256-A1 | PROSTAGLANDINE DERIVATIVE | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1995-08-09 | — | — | EP | disclosed |
| US-4052423-A | FROM A VINYLMERCURIC HALIDE, CARBON MONOXIDE AND ALCOHOL | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 1977-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016860-A1 | METHODS FOR PHOSPHINE OXIDE REDUCTION IN CATALYTIC WITTIG REACTIONS | DCXR, TECR, PWWP2B | HCAR2 3518/4885KEAP1 1468/4885NFE2L2 1044/4885 |
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | HCAR2 497/4885KEAP1 1885/4885NFE2L2 50/4885 |
| US-20180237441-A1 | Chemical Compounds | PSEN1, IRS1, CPT1A | HCAR2 4097/4885KEAP1 101/4885NFE2L2 888/4885 |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | HCAR2 497/4885KEAP1 1885/4885NFE2L2 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.